The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know
Top Cited Papers
Open Access
- 1 January 2011
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (1), 53-58
- https://doi.org/10.1210/jc.2010-2704
Abstract
This article summarizes the new 2011 report on dietary requirements for calcium and vitamin D from the Institute of Medicine (IOM). An IOM Committee charged with determining the population needs for these nutrients in North America conducted a comprehensive review of the evidence for both skeletal and extraskeletal outcomes. The Committee concluded that available scientific evidence supports a key role of calcium and vitamin D in skeletal health, consistent with a cause-and-effect relationship and providing a sound basis for determination of intake requirements. For extraskeletal outcomes, including cancer, cardiovascular disease, diabetes, and autoimmune disorders, the evidence was inconsistent, inconclusive as to causality, and insufficient to inform nutritional requirements. Randomized clinical trial evidence for extraskeletal outcomes was limited and generally uninformative. Based on bone health, Recommended Dietary Allowances (RDAs; covering requirements of ≥97.5% of the population) for calcium range from 700 to 1300 mg/d for life-stage groups at least 1 yr of age. For vitamin D, RDAs of 600 IU/d for ages 1–70 yr and 800 IU/d for ages 71 yr and older, corresponding to a serum 25-hydroxyvitamin D level of at least 20 ng/ml (50 nmol/liter), meet the requirements of at least 97.5% of the population. RDAs for vitamin D were derived based on conditions of minimal sun exposure due to wide variability in vitamin D synthesis from ultraviolet light and the risks of skin cancer. Higher values were not consistently associated with greater benefit, and for some outcomes U-shaped associations were observed, with risks at both low and high levels. The Committee concluded that the prevalence of vitamin D inadequacy in North America has been overestimated. Urgent research and clinical priorities were identified, including reassessment of laboratory ranges for 25-hydroxyvitamin D, to avoid problems of both undertreatment and overtreatment.Keywords
This publication has 9 references indexed in Scilit:
- Faculty Opinions recommendation of Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals.Published by H1 Connect ,2010
- Effects of Lowering Homocysteine Levels With B Vitamins on Cardiovascular Disease, Cancer, and Cause-Specific MortalityMeta-analysis of 8 Randomized Trials Involving 37 485 IndividualsEffects of Lowering Homocysteine LevelsArchives of Internal Medicine, 2010
- The Vitamin D and Cancer Conundrum: Aiming at a Moving TargetJournal of the American Dietetic Association, 2010
- Circulating 25-Hydroxyvitamin D and Risk of Pancreatic Cancer: Cohort Consortium Vitamin D Pooling Project of Rarer CancersAmerican Journal of Epidemiology, 2010
- Anticancer Vitamins du Jour--The ABCED's So FarAmerican Journal of Epidemiology, 2010
- 25-Hydroxyvitamin D Levels and the Risk of Mortality in the General PopulationArchives of Internal Medicine, 2008
- Vitamin D Deficiency and Risk of Cardiovascular DiseaseCirculation, 2008
- Effectiveness and safety of vitamin D in relation to bone health.2007
- Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admissionThe American Journal of Clinical Nutrition, 2006